NCT04508400View on ClinicalTrials.gov

Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

June 22, 2023

Study Completion Date

June 22, 2023

Conditions
Pediatric Cancer
Interventions
DRUG

Fosaprepitant,ondansetron, dexamethasone

Participants will randomly assigned 1:1 to receive double-blind study drug ( fosaprepitant plus ondansetron with dexamethasone OR placebo plus ondansetron with dexamethasone). Fosaprepitant or placebo to fosaprepitant were supplied and administered in a blinded manner.

DRUG

placebo ondansetron with dexamethasone

placebo plus ondansetron with dexamethasone

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER